Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.

ABSTRACT: Immunotherapies, including cell therapies, are effective anti-cancer agents. However, cellular product persistence can be limiting with short functional duration of activity contributing to disease relapse. A variety of manufacturing protocols are used to generate therapeutic engineered T cells; these differ in techniques used for T-cell isolation, activation, genetic modification, and other methodology. We sought to determine how pre-selection affected the phenotype of T cells engineered to secrete a CD123xCD3 bispecific engager (ENG-T). These cells were designed to treat acute myeloid leukemia (AML). We evaluated the effect of T-cell selection on transduction efficiency, T-cell activation, short- and long-term anti-AML cytotoxicity, and gene transcription. Unselected, CD4, CD8, and CD4/C

SUBMITTER: Holl NJ 

PROVIDER: S-EPMC12862316 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature